Source comparison
CJC-1295 vs Direct Growth Hormone Administration
CJC-1295 stimulates endogenous GH secretion; recombinant human growth hormone (rhGH) replaces it. The physiological difference is meaningful. Exogenous rhGH delivered subcutaneously bypasses the pituitary entirely, creating supraphysiological plasma GH concent
This comparison does not assign a generated winner or score.
- CJC-1295 stimulates endogenous GH secretion; recombinant human growth hormone (rhGH) replaces it. The physiological difference is meaningful. Exogenous rhGH delivered subcutaneously bypasses the pituitary entirely, creating supraphysiological plasma GH concentrations that suppress endogenous production through negative feedback at the hypothalamus. CJC-1295, by contrast, works within the body's existing feedback loops. It amplifies pulsatile secretion but doesn't abolish the pituitary's natural regulatory mechanisms.
- From a research standpoint, this distinction affects long-term axis recovery. Prolonged rhGH use can suppress endogenous GH production for weeks to months after cessation, requiring post-cycle intervention to restore pituitary function. CJC-1295 doesn't appear to cause the same degree of suppression. Studies show that GH pulse amplitude returns to baseline within 7–14 days of stopping CJC-1295, with no documented cases of prolonged hypogonadotropic hypogonadism in the published literature. The trade-off: rhGH produces more dramatic anabolic effects in the short term (lean mass gains of 3–5 kg over 8–12 weeks are common in research settings), while CJC-1295's effects are more gradual and conditional on training stimulus.
- Another practical difference: cost and accessibility. Pharmaceutical-grade rhGH costs $500–$1,200 per month at therapeutic doses; research-grade CJC-1295 from verified suppliers like Real Peptides runs $150–$300 per month at standard protocols. For researchers operating within budget constraints, CJC-1295 offers a more sustainable long-term model for investigating GH-mediated anabolic pathways.